Core Viewpoint - Innate Pharma will hold a conference call and webcast on March 26, 2026, to discuss its financial results for the full year ending December 31, 2025 [1]. Group 1: Conference Call Details - The conference call is scheduled for 2 p.m. CET / 9 a.m. EDT [1]. - A live webcast will be available at a specified link, and participants can also join via telephone using a registration link [2]. - A replay of the webcast will be accessible on the company website for 90 days following the event [2]. Group 2: Company Overview - Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients [3]. - The company specializes in antibody-engineering and innovative target identification to create next-generation antibody therapeutics [3]. Group 3: Product Pipeline - Innate Pharma is advancing a portfolio of differentiated potential first and/or best-in-class assets, including IPH4502, lacutamab, and monalizumab, targeting high unmet medical needs in oncology [4]. - IPH4502 is a Nectin-4 ADC for solid tumors, lacutamab is an anti-KIR3DL2 antibody for cutaneous T cell lymphomas, and monalizumab is an anti-NKG2A antibody developed in collaboration with AstraZeneca for non-small cell lung cancer [4]. Group 4: Collaborations - The company has established collaborations with leading biopharmaceutical companies such as Sanofi and AstraZeneca, as well as academic and research institutions to enhance innovation in immuno-oncology [5].

Summary of Innate Pharma Conference Call Company Overview - **Company**: Innate Pharma (NasdaqGS:IPHA) - **Date of Conference**: March 09, 2026 Key Programs Discussed 1. Nectin-4 ADC (IPH4502) - **Mechanism**: Targets Nectin-4 with a topoisomerase I payload, positioned as a growth driver for the company [2][5] - **Differentiation**: Compared to other Nectin-4 ADCs, IPH4502 has a superior antibody and linker, leading to better efficacy, especially in low Nectin-4 expression scenarios [7][8] - **Clinical Development**: Ongoing Phase 1 study in various tumor types, with potential indications in triple-negative breast cancer, prostate cancer, and non-small cell lung cancer [14][15] - **Study Size**: Expanded from 185 to approximately 120 patients, aiming for 10-15 patients in key tumor types to establish clinical signals [16] - **Data Release**: On track for data release by the end of Q2 2026, with a decision pending on whether to release early or wait for a more substantial dataset [21][22] 2. Lacutamab - **Type**: KIR3DL2 monoclonal antibody for cutaneous and peripheral T-cell lymphomas [38] - **Regulatory Status**: Received Breakthrough Therapy Designation (BTD) from the FDA, with an accelerated path to approval agreed upon [39] - **Confirmatory Study**: An umbrella protocol with two cohorts (Sézary syndrome and mycosis fungoides) is in place, comparing against active treatments [40] - **Funding Needs**: Currently seeking funding to initiate the confirmatory study, with options including strategic partnerships and equity raises [42][44] - **Market Potential**: High unmet medical need in early-stage patients, with potential to prevent disease progression [56] 3. Monalizumab - **Collaboration**: In partnership with AstraZeneca, focusing on early-stage lung cancer [71] - **Biological Rationale**: Combines with chemotherapy to enhance efficacy, supported by previous phase 2 studies showing improved progression-free survival (PFS) [72][73] - **Data Timeline**: Expected primary completion by the end of June 2026, with potential data release in the second half of the year [74] Financial Considerations - **Cash Runway**: Currently has cash through Q3 2026, exploring options to extend runway through royalty financing and potential equity raises [81][83] Additional Insights - **Market Dynamics**: The company is aware of competitive pressures in larger tumor settings and is focusing on differentiation through clinical signals and unmet needs [17][18] - **Regulatory Strategy**: Emphasizes the importance of strong clinical signals for investor confidence and market positioning [26] - **Potential for Early Use**: Lacutamab may be positioned for earlier treatment stages, creating a new market opportunity [56] This summary encapsulates the key points discussed during the conference call, highlighting the strategic direction and clinical development of Innate Pharma's leading programs.

Company Overview - Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients [3] - The company specializes in antibody-engineering and innovative target identification to create next-generation antibody therapeutics [3] Product Pipeline - Innate Pharma is advancing a portfolio of differentiated potential first and/or best-in-class assets, including: - IPH4502, a Nectin-4 ADC developed for solid tumors - Lacutamab, an anti-KIR3DL2 antibody for cutaneous T cell lymphomas and peripheral T cell lymphomas - Monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca for non-small cell lung cancer [4] Collaborations - The company has established partnerships with leading biopharmaceutical companies such as Sanofi and AstraZeneca, as well as renowned academic and research institutions to enhance innovation in immuno-oncology [5] Share Information - As of February 19, 2026, Innate Pharma has a total of 93,743,243 ordinary shares and 6,140 Preferred Shares from 2016 and 7,581 from 2017, resulting in a total of 94,484,443 theoretical voting rights [1] - The total number of exercisable voting rights is 94,465,868, calculated without considering shares held in treasury or with suspended voting rights [2]

Core Viewpoint - Innate Pharma SA has released its total number of shares outstanding and voting rights as of December 31, 2025, in compliance with French regulatory requirements [1]. Group 1 - The total number of shares outstanding for Innate Pharma SA is 93,719,323 ordinary shares [1]. - The announcement is made in accordance with article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation [1].

Core Points - Innate Pharma SA has announced its total number of shares outstanding and voting rights as of December 18, 2025, which amounts to 92,197,823 ordinary shares [1] Company Information - The total number of shares outstanding for Innate Pharma SA is 92,197,823 ordinary shares as of the specified date [1] - The announcement is in compliance with the French "Code de Commerce" and the regulations set by the Autorité des Marchés Financiers (AMF) [1]

Core Viewpoint - Innate Pharma SA has announced its financial calendar for 2026, detailing key dates for financial statements and shareholder meetings [1] Financial Calendar Summary - March 26, 2026: Publication of 2025 financial statements [1] - May 13, 2026: Publication of revenue and cash position for Q1 2026 [1] - May 21, 2026: Annual General Shareholders Meeting [1] - September 17, 2026: Publication of half-year financial statements [1] - November 5, 2026: Publication of revenue and cash position for Q3 2026 [1]

Summary of Innate Pharma Conference Call Company Overview - **Company**: Innate Pharma (NasdaqGS:IPHA) - **Industry**: Biotechnology, specifically focused on monoclonal antibodies and antibody-drug conjugates (ADCs) [3][4] Key Assets and Strategic Focus - **Current Assets**: Innate Pharma has eight assets in clinical development but is focusing on three key products: 1. **IPH4502**: Nectin-4 targeted ADC for solid tumors 2. **Lacutamab**: KIR3DL2 targeted antibody for cutaneous T-cell lymphoma (CTCL) 3. **Monalizumab**: NKG2A targeted antibody for stage III non-resectable non-small cell lung cancer (NSCLC) in collaboration with AstraZeneca [5][6] - **Organizational Changes**: The company downsized its workforce by 30% to allocate more resources towards advancing its clinical programs [6] Clinical Development Highlights Lacutamab - **Phase II Study**: Completed the TELLOMAK study for lacutamab, leading to a breakthrough therapy designation from the FDA for Sézary syndrome [7][21] - **Accelerated Approval Path**: The company has aligned with the FDA on a confirmatory phase III study for Sézary syndrome, which is expected to support a Biologics License Application (BLA) submission [7][8] - **Efficacy Data**: The phase II study showed an objective response rate of 42.9% and a progression-free survival (PFS) of 8.3 months in heavily pretreated patients [23] Monalizumab - **PACIFIC-9 Study**: Currently in a large randomized phase III study for NSCLC, with primary completion expected in June 2026. Positive results could yield $825 million in milestone payments [9][33] IPH4502 - **Differentiation**: IPH4502 is designed to target a broader range of Nectin-4 expressing tumors, including triple-negative breast cancer and prostate cancer. It utilizes an Exatecan payload, which has a different resistance profile compared to existing ADCs [10][12] - **Phase I Study**: Currently in phase I, with early signs of clinical activity observed at pharmacologically active doses [20][33] Market Potential and Commercial Strategy - **Sézary Syndrome**: Estimated 300 new patients annually in the U.S., with a potential market opportunity of up to $150 million [28][29] - **Mycosis Fungoides**: Approximately 3,000 new patients diagnosed each year, with a market potential of up to $500 million in the U.S. and Europe [29][30] - **Life Cycle Management**: Plans to expand the use of lacutamab to early-stage patients to improve quality of life and control symptoms [30] Upcoming Catalysts - **IPH4502 Data**: Expected data from the phase I study in early H1 next year [33] - **Lacutamab Phase III Initiation**: Anticipated to start in the first half of next year, leading to BLA submission for Sézary syndrome [34] - **PACIFIC-9 Results**: Primary endpoint results due in the second half of next year [34] Conclusion - Innate Pharma is strategically focusing on key assets with significant clinical and commercial potential, particularly in the treatment of rare cancers. The company is positioned for important upcoming milestones that could enhance its market presence and drive growth [34]

Core Insights - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] Group 1 - The article suggests that users may face blocks if ad-blockers are enabled, indicating a need to disable them for proper access [1]

Financial Data and Key Metrics Changes - The company ended Q3 2025 with a cash position of EUR 56.4 million, providing runway through the end of Q3 2026 to deliver on key milestones [26] Business Line Data and Key Metrics Changes - Lacutamab received FDA clearance to initiate the TELLOMAK III phase three trial in cutaneous T-cell lymphoma, with expectations for accelerated approval in Sézary syndrome based on robust phase two data [4][12] - IPH4502 is progressing well in its phase one trial, having reached a pharmacologically active dose and showing early signs of clinical activity [10][24] - Monalizumab is advancing in the PACIFIC-9 phase three trial, with top-line data expected in the second half of 2026 [11][24] Market Data and Key Metrics Changes - The annual incidence of Sézary syndrome is estimated at around 300 patients, with a prevalence of approximately 1,000 diagnosed patients in the U.S. [19] - For mycosis fungoides, approximately 3,000 new patients are diagnosed each year in the U.S., with one in four receiving systemic therapy [20] Company Strategy and Development Direction - The company is focusing investments on high-value clinical assets, including IPH4502, Lacutamab, and Monalizumab, while advancing next-generation ADC programs [6][24] - The development strategy for Lacutamab includes a stepwise approach starting with Sézary syndrome, followed by mycosis fungoides, and expanding to peripheral T-cell lymphoma [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the regulatory path for Lacutamab, indicating that the FDA has not requested additional substantial analyses beyond existing phase two data for accelerated approval [31] - There is growing momentum among KOLs for Lacutamab to become the preferred second-line option, with expectations that it may be used ahead of Mogamulizumab in mycosis fungoides [32][33] Other Important Information - The company is streamlining its organization to align with strategic objectives and ensure it remains fit for purpose [6] - The confirmatory phase three trial for Lacutamab is set to begin in the first half of 2026, with a potential BLA submission anticipated in early 2027 [12][31] Q&A Session Summary Question: What needs to be done for the potential Lacutamab commercial launch in Sézary syndrome? - The company aims to ensure Lacutamab is included in the NCCN guidelines prior to the BLA approval [27][28] Question: What can be expected from the upcoming data set for IPH4502? - The company hopes to present data from a cohort of patients in the Padcev resistance setting, with an interesting response rate and safety data [28][29] Question: Is the FDA looking for additional analyses for Lacutamab's accelerated approval? - The FDA has not indicated a need for further substantial analyses; the BLA approval will be based on existing TELLOMAK study data [31] Question: What are the expectations for the PACIFIC-9 study readout? - The company has good expectations based on previous studies, anticipating a positive outcome for the PACIFIC-9 study [40]

Q3 2025 Business Update and Financial Results November 13 2025 This document contains data pertaining to the Company's potential markets and the industry and environment in which it operates. Some of this data comes from external sources that are recognized in the field or from Company's estimates based on such sources. This presentation discusses product candidates that are under clinical development, and which have not yet been approved for marketing by the U.S. Food and Drug Administration or the Europea ...